BUPRENEX
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BUPRENEX is a small-molecule injectable opioid analgesic approved in 1981 for pain management. The drug contains buprenorphine, a partial mu-opioid receptor agonist with ceiling effects on respiratory depression. It is indicated for moderate to severe pain and is commonly used in perioperative settings and chronic pain management.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) suggests smaller brand team and focus on defensive strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BUPRENEX offers limited career growth opportunities given the product's LOE-approaching lifecycle and minimal linked job openings. Career value lies in defending market share in a mature opioid category, making this role more suitable for experienced professionals managing decline rather than driving innovation.
Brand ManagerField Sales Representative
Worked on BUPRENEX at Indivior? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.